|
|
| Undisclosed HBV therapeutic / Kainos Medicine, Institut Pasteur Korea (0 Trials) |
|
| Undisclosed HBV therapeutic / Shanghai Jinwei Biotechnology, TheraVectys (0 Trials) |
|
| Undisclosed HBV therapeutic 1 / The Pop Test & Palisades Therap (0 Trials) |
|
| Undisclosed HBV therapeutic 2 / The Pop Test & Palisades Therap (0 Trials) |
|
| Undisclosed HBV therapy / Ascletis (0 Trials) |
|
| Undisclosed HBV therapy / AiCuris (0 Trials) |
|
| Undisclosed HBV therapy / Collaborations Pharma (0 Trials) |
|
| Undisclosed HBV therapy / ViroStatics (0 Trials) |
|
| Undisclosed hemophilia A therapeutic / Recursion Pharma (0 Trials) |
|
| Undisclosed hemophilia A therapeutic / Lambdagen Therap (0 Trials) |
|
| Undisclosed hemophilia A therapeutic / Generation Bio (0 Trials) |
|
| Undisclosed HER2 vaccine / International Cancer Lab (0 Trials) |
|
| Undisclosed HER2-Exon 20 targeting therapeutic / Pfizer (0 Trials) |
|
| Undisclosed HER2-targeting DNase-armored CAR T / Xenetic Biosci (0 Trials) |
|
| Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute (1 Trials) |
|
| Undisclosed HER2xCD28 bispecific TCE POWERbody / Adagene (0 Trials) |
|
| Undisclosed HIF-1α inhibitor / Olipass (0 Trials) |
|
| Undisclosed HPK1 degrader / Arvinas (0 Trials) |
|
| Undisclosed HPK1 degrader / Cullinan Oncology (0 Trials) |
|
| Undisclosed HPV E6 inhibitor / Kovina (0 Trials) |
|
| Undisclosed Huntington disease gene therapy / Locana (0 Trials) |
|
| Undisclosed Huntington’s disease therapeutic / Anima Biotech, Takeda (0 Trials) |
|
| Undisclosed IAP antagonist / Sanford-Burnham Medical Research Institute (0 Trials) |
|
| Undisclosed IAP inhibitor / HEC Pharm (0 Trials) |
|
| Undisclosed IBD therapeutic / ChironWells (0 Trials) |
|
| Undisclosed IBD therapeutic / Cloud Pharma (0 Trials) |
|
| Undisclosed IBD therapeutic / Novome Biotech (0 Trials) |
|
| Undisclosed IBD therapeutic / Antibe (0 Trials) |
|
| Undisclosed IBD therapeutic / Takeda, Engitix (0 Trials) |
|
| Undisclosed IBD therapeutic / Portage (0 Trials) |
|
| Undisclosed IBD therapeutic / BMS (0 Trials) |
|
| Undisclosed IBD therapeutic / Synlogic, Roche (0 Trials) |
|
| Undisclosed IBD therapeutic / BioIncept (0 Trials) |
|
| Undisclosed IBD therapeutic / Draconis Pharma (0 Trials) |
|
| Undisclosed IBD therapeutic / Captor Therap, Sosei (0 Trials) |
|
| Undisclosed IBD therapeutic / Renexxion (0 Trials) |
|
| Undisclosed IBD therapeutic / Lumen Bio (0 Trials) |
|
| Undisclosed ICL4 targeting CF therapeutic / Sionna Therap (0 Trials) |
|
| Undisclosed idiopathic pulmonary fibrosis cough therapeutic / Nocion Therap (0 Trials) |
|
| Undisclosed idiopathic pulmonary fibrosis therapeutic / Ergon Pharma (0 Trials) |
|
| Undisclosed IEM therapeutic / Agios Pharma (0 Trials) |
|
| Undisclosed IgM based bispecific antibody / IGM Biosciences (0 Trials) |
|
| Undisclosed IL-10 partial agonist program / Synthekine (0 Trials) |
|
| Undisclosed IL-12 based therapy / Obsidian, BMS (0 Trials) |
|
| Undisclosed IL-4/IL-13 kinoid / Neovacs (0 Trials) |
|
| Undisclosed IL-4Rα antagonist / Ventyx Biosci (0 Trials) |
|
| Undisclosed immune evasion therapeutic / Tango Therap, Gilead (0 Trials) |
|
| Undisclosed immune modulation therapy research program / Celldex (0 Trials) |
|
| Undisclosed immune normalizer / Normunity (0 Trials) |
|
| Undisclosed immunomodulatory proteins / Compugen (0 Trials) |
|
| Undisclosed immunotherapeutic prostate cancer vaccine / Ohana Vaccine (0 Trials) |
|
| Undisclosed inherited retinal dystrophy therapeutic / PTC Therap (0 Trials) |
|
| Undisclosed iNK and iT cell therapy / Fate Therap (0 Trials) |
|
| Undisclosed iNK cell therapy / Century Therap (0 Trials) |
|
| Undisclosed iNKT cell engager / Agenus (0 Trials) |
|
| Undisclosed interferonopathies therapeutic / Galapagos (0 Trials) |
|
| Undisclosed interleukin-2 modulator mAb / Xoma, Zydus Lifesci (0 Trials) |
|
| Undisclosed ion channel modulator / Autifony Therap (0 Trials) |
|
| Undisclosed IPF therapeutic / LISCure Biosci (0 Trials) |
|
| Undisclosed IPF therapeutic / Omega Therap (0 Trials) |
|
| Undisclosed IPF therapeutic / Surrozen (0 Trials) |
|
| Undisclosed iPSC-derived γδ-CAR T / Century Therap (0 Trials) |
|
| Undisclosed IRAK4/BTK inhibitor / Fosun Pharma (0 Trials) |
|
| Undisclosed JAK inhibitor / Arctoris, Insilico Medicine (0 Trials) |
|
| Undisclosed KATP inhibitor / Cephagenix (0 Trials) |
|
| Undisclosed KIF18A inhibitor / Satya Pharma (0 Trials) |
|
| Undisclosed KRAS degrader / Progenra (0 Trials) |
|
| Undisclosed KRAS G12D degrader / SEED Therapeutics (0 Trials) |
|
| Undisclosed KRAS G12D inhibitor / BMS (0 Trials) |
|
| Undisclosed KRAS G12D inhibitor / Curve Therap (0 Trials) |
|
| Undisclosed KRAS G12D-specific PROTAC degrader / Arvinas (0 Trials) |
|
| Undisclosed KRAS G12V-specific PROTAC degrader / Arvinas (0 Trials) |
|
| Undisclosed KRAS inhibitor / Oblique Therap (0 Trials) |
|
| Undisclosed KRAS-G12D TCR-modified T-cell therapy / Anocca (0 Trials) |
|
| Undisclosed KRAS4B inhibitor / Immuneering (0 Trials) |
|
| Undisclosed KRASG12D iTAb inhibitor / Sorrento (0 Trials) |
|
| Undisclosed Ku-DNA binding inhibitor / NERx Biosci (0 Trials) |
|
| Undisclosed Kv1.3 blocker / Muna Therap (0 Trials) |
|
| Undisclosed Kv3.1/Kv3.2 activator / Bionomics (0 Trials) |
|
| Undisclosed LAG-3 inhibitor / Trellis Biosci (0 Trials) |
|
| Undisclosed LAG-3 targeted IL15/IL15Rα-Fc therapeutic / Xencor (0 Trials) |
|
| Undisclosed lncRNA based cancer therapeutic / HAYA Therap (0 Trials) |
|
| Undisclosed LRRK2 inhibitor / Schrodinger (0 Trials) |
|
| Undisclosed LRRK2 inhibitor therapeutic / AbbVie (0 Trials) |
|
| Undisclosed Lysosomal Channel 1 therapeutic / Autifony Therap, Boehringer Ingelheim (0 Trials) |
|
| Undisclosed Lysosomal channel 2 therapeutic / Autifony Therap (0 Trials) |
|
| Undisclosed M4 Agonist / AbbVie (0 Trials) |
|
| Undisclosed MALT1 inhibitor / C4X Discovery (0 Trials) |
|
| Undisclosed MAP Kinase Kinase 2 inhibitors / Pfizer (0 Trials) |
|
| Undisclosed MAP-Tau based therapeutic / PTC Therap (0 Trials) |
|
| Undisclosed MAS1 modulator therapeutic / Omeros (0 Trials) |
|
| Undisclosed masked antibodies / Adagene, Sanofi (0 Trials) |
|
| Undisclosed MASP-2 inhibitor therapeutic / Omeros (0 Trials) |
|
| Undisclosed MASP-2/3 inhibitor therapeutic / Omeros (0 Trials) |
|
| Undisclosed MASP-3 inhibitor therapeutic / Omeros (0 Trials) |
|
| Undisclosed MAT2A inhibitor / Lupin (0 Trials) |
|
| Undisclosed MAT2A inhibitor / Ryvu Therap (0 Trials) |
|
| Undisclosed mbIL-15 TCR T-cell therapy / Alaunos Therap (0 Trials) |
|
| Undisclosed MC2 antagonist / OMass Therap (0 Trials) |
|
| Undisclosed mHTT targeted PROTAC degrader / Arvinas (0 Trials) |
|
| Undisclosed MICA/BxB7H3 NKE / Xencor (0 Trials) |
|
| Undisclosed MPS I gene therapy / CRISPR Therap (0 Trials) |
|
| Undisclosed MRGE modulator therapeutic / Omeros (0 Trials) |
|
| Undisclosed mRNA based cancer vaccine / Pantherna Therap, Evaxion (0 Trials) |
|
| Undisclosed mRNA modulator / Anima Biotech, AbbVie (0 Trials) |
|
| Undisclosed mRNA-based CAR-T immunotherapy / Strand Therap (0 Trials) |
|
| undisclosed MSA therapeutic / MitoDys Therap (0 Trials) |
|
| Undisclosed MSC-derived Exosomes with KrasG12D siRNA / UT MD Anderson Cancer Center (0 Trials) |
|
| Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine / University of Pittsburgh (4 Trials) |
|
| Undisclosed multi-targeted kinase inhibitor / Harmonic Discovery (0 Trials) |
|
| Undisclosed multiple myeloma γδ cell therapy / Adicet Bio (0 Trials) |
|
| Undisclosed mutant KRAS inhibitor / BMS (0 Trials) |
|
| Undisclosed mutant selective ErbB2 inhibitor / Cogent Biosci (0 Trials) |
|
| Undisclosed mutant-specific KRAS inhibitor / Roche (0 Trials) |
|
| Undisclosed myostatin inhibitor / PeptiDream (0 Trials) |
|
| Undisclosed NBD1 targeting CF therapeutic / Sionna Therap (0 Trials) |
|
| Undisclosed nectin4 ADC / CSPC Pharma (0 Trials) |
|
| Undisclosed neuroscience therapeutic / Jazz (0 Trials) |
|
| Undisclosed neurovascular channel modulator / Autifony Therap (0 Trials) |
|
| Undisclosed next gen LSD1 inhibitor / Salarius (0 Trials) |
|
| Undisclosed next generation fD inhibitors / AstraZeneca (0 Trials) |
|
| Undisclosed next generation telomerase inhibitor / Geron (0 Trials) |
|
| Undisclosed next-generation ADC / Eli Lilly, AbbVie (0 Trials) |
|
| Undisclosed next-generation immunotherapeutic / GemVax & KAEL (0 Trials) |
|
| undisclosed next-generation TCR-T cell therapy / ImmunoScape (0 Trials) |
|
| Undisclosed NK+T / Nkarta Therap, CRISPR Therap (0 Trials) |
|
| Undisclosed NLRP3 inhibitor / Halia Therap (0 Trials) |
|
| Undisclosed NOTCH inhibitor / Exelixis, StemSynergy Therap (0 Trials) |
|
| Undisclosed NOX2 activator / ProNoxis (0 Trials) |
|
| Undisclosed NR2F6 agonist / Regen BioPharma (0 Trials) |
|
| Undisclosed NRAS inhibitor / FogPharma (0 Trials) |
|
| Undisclosed Nrf2-ARE activators / Keapstone Therap (0 Trials) |
|
| Undisclosed oncology therapeutic / (0 Trials) |
|
| Undisclosed OPN4 modulator therapeutic / Omeros (0 Trials) |
|
| Undisclosed oral LSD1 inhibitor / EpiAxis Therap (0 Trials) |
|
| Undisclosed ovarian cancer therapeutic / Immune Biosolutions (0 Trials) |
|
| Undisclosed ovarian cancer vaccine / Anixa Biosci (0 Trials) |
|
| Undisclosed p21 activated kinase inhibitor / BMS (0 Trials) |
|
| Undisclosed P2Y8 modulator therapeutic / Omeros (0 Trials) |
|
| Undisclosed p53 oligomer inhibitor / Treventis Corp (0 Trials) |
|
| Undisclosed PAD inhibitor / BMS, Evotec (0 Trials) |
|
| Undisclosed pan-KRAS inhibitor / FogPharma (0 Trials) |
|
| Undisclosed pan-RAF inhibitor / Voronoi, METiS Therap (0 Trials) |
|
| Undisclosed pan-TEAD inhibitor / FogPharma (0 Trials) |
|
| Undisclosed pancreatic cancer therapeutic / Immune Biosolutions (0 Trials) |
|
| Undisclosed panFLT3 inhibitor / Kurome (0 Trials) |
|
| Undisclosed PAR2 pepducin / Oasis Pharma (0 Trials) |
|
| Undisclosed PARG inhibitor / Satya Pharma (0 Trials) |
|
| Undisclosed Parkinson's disease gene therapy / Exegenesis Bio (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutic / New Biotic (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutic / NeuroPn (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutic / MitoDys Therap (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutic / AEterna Zentaris (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutic / Portage (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutic / Verge Genomics (0 Trials) |
|
| Undisclosed Parkinson's disease therapeutics / Servier, University of Barcelona (0 Trials) |
|
| Undisclosed Parkinson’s disease therapeutic / Arkuda Therap (0 Trials) |
|
| Undisclosed PARP inhibitor / NeoTX (0 Trials) |
|
| Undisclosed PARP1 inhibitor / Waverley Pharma (0 Trials) |
|
| Undisclosed PARP1 inhibitor / Denovicon (0 Trials) |
|
| Undisclosed PARP1/CDK dual inhibitor / Accutar Biotech (0 Trials) |
|
| Undisclosed PARP2 inhibitor / Denovicon (0 Trials) |
|
| Undisclosed PARP7 inhibitor / Insilico Medicine (0 Trials) |
|
| Undisclosed PARP7 inhibitor / Duke Street Bio (0 Trials) |
|
| Undisclosed PARP7 inhibitor / Denovicon (0 Trials) |
|
| Undisclosed Partnered TriNKETs / Dragonfly Therap, BMS (0 Trials) |
|
| Undisclosed PD-1 inhibitor / BMS (0 Trials) |
|
| Undisclosed PD-1 monoclonal antibody / Jiangsu Pacific Meinuoke Biopharmaceutical (0 Trials) |
|
| Undisclosed PD-1 x CTLA-4 trispecific TRIDENT / MacroGenics (0 Trials) |
|
| Undisclosed PD-L1 inhibitor / NeoTX (0 Trials) |
|
| Undisclosed PD-L1 mAb / JSR Life Sciences (0 Trials) |
|
| Undisclosed PD-L1/BCMA bispecific antibody therapeutic / Immune Pharma (0 Trials) |
|
| Undisclosed PD-L1/CTLA-4 bispecific antibody therapeutic / Sorrento (0 Trials) |
|
| Undisclosed PD1 antagonist mAb / North Coast Biologics (0 Trials) |
|
| Undisclosed PD1 x IL15/IL15Rα bispecific antibody therapeutic / Xencor (0 Trials) |
|
| Undisclosed PD1 x TGFβR2 XmAb therapeutic / Xencor (0 Trials) |
|
| Undisclosed PD1-TIM3 bispecific antibody / BMS (0 Trials) |
|
| Undisclosed PD1/LILRB1 BiTE / Amgen (0 Trials) |
|
| Undisclosed PDE4B inhibitor / Shionogi (0 Trials) |
|
| Undisclosed PDL1 x CD28 XmAb bsAb therapeutic / Xencor (0 Trials) |
|
| Undisclosed personalized mRNA-based vaccine / Greenlight Biosci, EpiVax (0 Trials) |
|
| Undisclosed PI3K/PARP dual inhibitor / SignalRx (0 Trials) |
|
| Undisclosed PKC theta inhibitor / EpiAxis Therap (0 Trials) |
|
| Undisclosed PKCθ modulator / Evommune (0 Trials) |
|
| Undisclosed PKMYT1 inhibitor / Acrivon Therap (0 Trials) |
|
| Undisclosed PLK1 inhibitor / Fosun Pharma (0 Trials) |
|
| Undisclosed PLK1 PROTAC / Icure Pharm (0 Trials) |
|
| Undisclosed PLK4 inhibitor / Qilu Pharma (0 Trials) |
|
| Undisclosed post-infection cough therapeutic / Nocion Therap (0 Trials) |
|
| Undisclosed PRMT5 inhib / Lupin (0 Trials) |
|
| Undisclosed PRMT5 inhib / Lead Pharma (0 Trials) |
|
| Undisclosed PRMT5 inhib / Ohio State University (0 Trials) |
|
| Undisclosed prostate cancer therapeutic / Esfam Biotech (0 Trials) |
|
| Undisclosed prostate cancer therapeutic / Philogen (0 Trials) |
|
| Undisclosed PROTAC degrader / Arvinas, Bayer (0 Trials) |
|
| Undisclosed PROTAC degrader / Pin Therap (0 Trials) |
|
| Undisclosed protease inhibitor / Virna Therap (0 Trials) |
|
| Undisclosed Protein A degrader / Degron Therap (0 Trials) |
|
| undisclosed protein degradation therapeutic / Amgen, Plexium (0 Trials) |
|
| Undisclosed protein degradation therapeutic / Frontier Medicines, AbbVie (0 Trials) |
|
|